Spanish doctors demonstrate the effectiveness of a new antibiotic against serious infections

Two specialists from the Virgen del Rocío University Hospital in Seville jointly conducted clinical trials of a new antibiotic. effective against multi-resistant bacteria in serious infections.

New antimicrobial drug called aztreonam-avibactam, It has been highly anticipated as it is very active against common bacteria such as Klebsiella pneumoniae and Escherichia coli, mainly when they are resistant to multiple antibiotics, especially carbapenams, for which the available treatment options are very limited.

The study was conducted in 87 countries and included more than 400 patients with complicated intra-abdominal infections and pneumonia in whom this new therapeutic option was compared with standard treatment. Titled “Revisit,” it was published in one of the most influential scientific journals, “The Lancet Infectious Diseases,” thereby confirming the results obtained with the use of aztreonam-avibactam.

Thanks to these data, the new antibiotic was approved by the European Medicines Agency (EMA). This is possible thanks to a fast-track assessment mechanism given that it is “of great public health interest”as highlighted by José Miguel Cisneros, director of the department of infectious diseases, microbiology and parasitology of the Seville hospital and principal investigator of the study. Surgeon Rosa Maria Jimenez Rodriguez from the General Surgery Department of the same center also took an active part.